Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography–tandem mass spectrometry

References

• Vidensek N, Lim P, Campbell A, Carlson C. Taxol content in bark, wood, root, leaf, twig, and seedling from several taxus species. J Nat Prod. 1990;53(6):1609−1610. doi:10.1021/np50072a0391982448
   PubMed Web of Science ®Google Scholar
• Adams JD, Flora KP, Goldspiel BR, et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr. 1993;(15):141–147.7912520
   PubMedGoogle Scholar
• Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P.Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol. 1986;17(2):137–142. doi:10.1007/BF003067422872974
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990;82(15):1247–1259.1973737
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Van AJ, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031–2035. doi:10.1073/pnas.94.5.20319050899
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590–1598. doi:10.1016/S0959-8049(01)00171-X11527683
   PubMed Web of Science ®Google Scholar
• Kong L, Askes SHC, Bonnet S, Kros A, Campbell F. Temporal control of membrane fusion through photolabile PEGylation of liposome membranes. Angew Chem Int Ed. 2016;55(4):1396–1400. doi:10.1002/anie.201509673
   PubMed Web of Science ®Google Scholar
• Sharma N, Madan P, Lin S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: a co-surfactant study. Asian J Pharm Sci. 2016;11(3):404–416. doi:10.1016/j.ajps.2015.09.004
   Web of Science ®Google Scholar
• Han X, Chen J, Jiang M, et al. Paclitaxel–paclitaxel prodrug nanoassembly as a versatile nanoplatform for combinational cancer therapy. ACS Appl Mater Interfaces. 2016;8(49):33506–33513. doi:10.1021/acsami.6b1305727960378
   PubMed Web of Science ®Google Scholar
• Sofias AM, Dunne M, Storm G, Allen C. The battle of “nano” paclitaxel. Adv Drug Delivery Rev. 2017;122:20–30. doi:10.1016/j.addr.2017.02.003
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803. doi:10.1200/JCO.2005.04.93716172456
   PubMed Web of Science ®Google Scholar
• Cheng HR, Guan H, Chen J. Efficacy and safety of abraxane and paclitaxel liposome in treatment of recurrent ovarian cancer. J Pract Obstet Gynecol. 2015;31(3):229–232.
   Google Scholar
• Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611–3619. doi:10.1200/JCO.2008.18.539719470941
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Damascelli B, et al. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59–64.19412420
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041–1053. doi:10.1517/14656566.7.8.104116722814
   PubMed Web of Science ®Google Scholar
• Desai N. Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor-derived SPARC for targeting. Drug Deliv Rep. 2007;37–41.
   Google Scholar
• Desai N. Nanoparticle Albumin-Bound Anticancer Agents. In: Crommelin D., de Vlieger J. (eds) Non-Biological Complex Drugs Non-Biological Complex Drugs. AAPS Advances in the Pharmaceutical Sciences Series, Springer, Cham; 2015;20:335–354
   Google Scholar
• Stern ST, Martinez MN, Stevens DM. When is it important to measure unbound drug in evaluating nanomedicine pharmacokinetics? Drug Metabo Dispos. 2016;44(12):1934–1939. doi:10.1124/dmd.116.073148
   PubMed Web of Science ®Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200–4205. doi:10.1158/1078-0432.CCR-07-459218594000
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet. 1992;23(6):449–468. doi:10.2165/00003088-199223060-000051458763
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang Y, Huo Y, Chang Y-X, Liu E-W, Hao J. Monitoring unbound warfarin in drug combination therapy by pharmacokinetics and fluorospectrometry. Chin Herbal Med. 2019;11(1):92–97. doi:10.1016/j.chmed.2018.10.002
   Web of Science ®Google Scholar
• Tsai TH. Chapter 6.5 Assaying protein-unbound drugs using microdialysis techniques. Tech Behav Neural Sci. 2006;16:573–587.
   Google Scholar
• Waters NJ, Jones R, Williams G, Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci. 2010;97(10):4586–4595. doi:10.1002/jps.21317
   Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Contains nonbinding recommendations: draft guidance on paclitaxel; 2012 Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM320015.pdf.Recommended. Accessed October 22, 2017.
   Google Scholar
• Committee for Proprietary Medicinal Products (CPMP),The European Agency for the Evaluation of Medicinal Products (EMA). Note for Guidance on the Investigation of Bioavailability and Bioequivalence.CPMP/EWP/QWP/1401/98Rev.1; 2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientifc_guideline/2010/01/WC500070039. Accessed 87, 2013.
   Google Scholar
• Food and Drug Administration (FDA). Guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA; 2013 Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf. Accessed October 22, 2017.
   Google Scholar
• Li QM, Zhang H, Zhu XX, et al. Tolerance, variability and pharmacokinetics of albumin-bound paclitaxel in chinese breast cancer patients. Front Pharmacol. 2018;9:1372. doi:10.3389/fphar.2018.0137230559662
   PubMed Web of Science ®Google Scholar
• Kumar GN, Walle UK, Bhalla KN, et al. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol. 1993;80(3):337–344.8102493
   PubMedGoogle Scholar
• Brouwer E, Verweij J, De Bruijn P, et al. Measurement of fraction unbound paclitaxel in human plasma[J]. Drug Metab Dispos. 2000;28(10):1141–1145.10997930
   PubMed Web of Science ®Google Scholar
• Sottani C, Minoia C, D’Incalci M, Paganini M, Zucchetti M. High‐performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol®) in human plasma. Rapid Commun Mass Spectrom. 1998;12(5):251–255. doi:10.1002/(ISSN)1097-02319519477
   PubMed Web of Science ®Google Scholar
• Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B. 2003;783(1):231–236. doi:10.1016/S1570-0232(02)00659-1
   PubMed Web of Science ®Google Scholar
• Mortier KA, Renard V, Verstraete AG, Van Gussem A, Van Belle S, Lambert WE. Development and validation of a liquid chromatography−tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid. Anal Chem. 2005;77(14):4677–4683. doi:10.1021/ac050094116013889
   PubMed Web of Science ®Google Scholar
• Zhang SQ, Chen GH. Determination of paclitaxel in human plasma by UPLC–MS–MS. J Chromatogr Sci. 2008;46(3):220–224. doi:10.1093/chromsci/46.3.22018334088
   PubMed Web of Science ®Google Scholar
• Fan YX, Chen XY, Ma ZY, et al. Determination of paclitaxel and hydroxylated metabolites in rat plasma with lithium adduct ion by LC–MS/MS. J Chin Mass Spectr Soc. 2013;34(3):137–144.
   Google Scholar
• Wu HL, Ma ZY, Zhang SQ, et al. Effects of different formulations on plasma free concentration of paclitaxel in rats. Chin J Pharm. 2016;47(11):1430–1435.
   Google Scholar
• Gardner ER, Dahut W, Figg WD. Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B. 2008;862:213–218. doi:10.1016/j.jchromb.2007.12.013
   PubMed Web of Science ®Google Scholar
• Bulitta JB, Zhao P, Arnold RD, et al. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer Chemother Pharmacol. 2009;63(6):1049–1063. doi:10.1007/s00280-008-0827-218791718
   PubMed Web of Science ®Google Scholar
• Li S, Liao H, Zhan J, et al. Comparison the pharmacokinetics of nanoparticle albumin bound paclitaxel and solvent based paclitaxel in breast cancer patients. Chin J Clin Pharmacol. 2010;26(8):606–610.
   Google Scholar
• Bian L, Geng CZ, Ouyang QC, et al. Study of bioequiavailability of paclitaxel for injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer. Natl Med J China. 2018;98(16):1236–1241.
   Google Scholar
• Mosteller RD. Simplified calculation of body surface area. N Engl J Med. 1987;317:1098. doi:10.1056/NEJM1987071631703013657876
   PubMed Web of Science ®Google Scholar
• Mortier KA, Lambert WE. Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry. J Chromatog A. 2006;1108(2):195–201. doi:10.1016/j.chroma.2005.12.10316472531
   PubMed Web of Science ®Google Scholar